Risankizumab is a humanized IgG1 monoclonal antibody (mAb) that targets interleukin 23 (IL-23). It has been used for the treatment of moderate-to-severe plaque psoriasis
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company